Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

Exclusion Criteria

• •Women who are pregnant or breast feeding
• •History of brain and/or leptomeningeal metastases
• •Previous chemotherapy for metastatic breast cancer
• •Past or current history of malignant neoplasm other than breast carcinoma, except for curatively treated non melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
• •Pre-existing neuropathy grade 1 according to the NCIC-CTC 3.0
• •Psychiatric disorders or other conditions which would prevent pt. compliance
• •Other serious illness or medical condition:
• •* Congestive heart failure, or unstable angina pectoris, previous history of myocardial infarction within 6 month prior to study entry, uncontrolled hypertension as determined by the Investigator or high risk uncontrolled, arrhythmia.
• •* History of significant neurological or psychiatric disorders including psychotic disorders, dementia of seizures that would prohibit the understanding and giving of informed consent.
• •* Active uncontrolled infection.
• •* Unstable peptic ulcer, unstable diabetes mellitus or other contraindication for the use of Corticosteroids.
• •Inability to take and/or absorb oral medicine
• •Prior treatment with an docetaxel and/or capecitabine and/or vinorbine
• •Concurrent treatment with other experimental drugs, or participation in another clinical trial with any investigational drug within 30 days prior to study entry